Q1 Earnings Estimate for ATNM Issued By HC Wainwright

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – HC Wainwright issued their Q1 2026 EPS estimates for shares of Actinium Pharmaceuticals in a report issued on Tuesday, March 31st. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($0.22) per share for the quarter. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.29) EPS and Q4 2026 earnings at ($0.33) EPS.

Separately, Stephens reaffirmed an “overweight” rating and set a $5.00 price objective on shares of Actinium Pharmaceuticals in a research note on Tuesday. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Actinium Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $4.50.

Actinium Pharmaceuticals Trading Down 1.0%

Shares of NYSE:ATNM opened at $0.98 on Wednesday. Actinium Pharmaceuticals has a 12-month low of $0.95 and a 12-month high of $1.95. The company has a market capitalization of $30.76 million, a PE ratio of -0.71 and a beta of -0.21. The business has a 50 day moving average of $1.13 and a two-hundred day moving average of $1.35.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Mayport LLC acquired a new position in Actinium Pharmaceuticals in the 3rd quarter worth about $35,000. AM Investment Strategies LLC acquired a new stake in Actinium Pharmaceuticals in the fourth quarter valued at approximately $40,000. Qube Research & Technologies Ltd purchased a new stake in shares of Actinium Pharmaceuticals in the second quarter valued at approximately $70,000. Bailard Inc. purchased a new stake in shares of Actinium Pharmaceuticals in the fourth quarter valued at approximately $79,000. Finally, AQR Capital Management LLC raised its stake in shares of Actinium Pharmaceuticals by 278.6% during the 1st quarter. AQR Capital Management LLC now owns 63,249 shares of the company’s stock worth $102,000 after buying an additional 46,545 shares during the period. Hedge funds and other institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.